After lots were drawn when three rounds of voting failed to produce a winner, Amsterdam beat Milan to become the new hometown of the European Medicines Agency.
EMA is crucial to guaranteeing patient safety in Europe: the agency supervises medicines for both human and animal use and helps national authorities authorise the sale of drugs across the EU's single market of some 500 million people. It has been based in London since 1995 and employs about 900 people.After its relocation in 2019, EMA's headquarters will be a tailor-made building in Amsterdam’s Zuidas business district.
This Brexit-induced move is great news, says Ruud Smits, co-head of NautaDutilh's Life Sciences and Technology teams, "as the relocation of EMA promises to make the greater Amsterdam area, including Leiden and Utrecht, into the hub for Europe's pharma industry. Combined with the expertise the Netherlands already has in this field, our great infrastructure and close cooperation within the Benelux, this will really get everybody involved. And naturally, we as Life Sciences and Technology legal experts look forward to work together with any newcomer or anybody who has any questions regarding the EMA's new home."